Table of Content

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates
1.1 Overview
1.2 Comparison With Other Immunotherapies


2. Need For Bispecific Antibody Drug Conjugates


3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action
3.1 General Structure & Design
3.2 Mechanism Of Action


4. Global Bispecific Antibody Drug Conjugate Market Insight
4.1 Current Market Scenario
4.2 Future Market Opportunity


5. Bispecific Antibody Drug Conjugates Market Analysis by Region
5.1 China
5.2 US
5.3 Europe
5.4 South Korea


6. Bispecific Antibody Drug Conjugates – Application & Development By Indication
6.1 Breast Cancer
6.2 Gastrointestinal Cancer
6.3 Lung Cancer
6.4 Urologic Cancers
6.5 Gynecologic Cancers


7. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview
7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Phase


8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III


9. Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates

This Chapter Gives Comprehensive Insight On More Than 15 Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates


10. Competitive Landscape
10.1 Almac Discovery
10.2 Alphamab Oncology
10.3 Amgen
10.4 ArbeleBio
10.5 AstraZeneca
10.6 Beijing Biocytogen
10.7 BiVictriX Therapeutics
10.8 Bright Biologics
10.9 Corellia AI
10.10 CStone Pharmaceuticals
10.11 Debiopharm
10.12 Doma Bio
10.13 DualityBio
10.14 Enduring Biotech
10.15 Genmab
10.16 InduPro
10.17 Innovent Biologics
10.18 Kanaph Therapeutics
10.19 ProEn Therapeutics
10.20 Synaffix



List of Figures

Figure 1-1: Future Directions In BsADC Development
Figure 1-2: Limitations Of Convectional Immunotherapies Addressable By BsADCs

Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate – General Mechanism of Action

Figure 4-1: Bispecific Antibody Drug Conjugate Market forecast – Projections For First 12 & 24 Months Post-Approval Of First Drug (US$ Million)
Figure 4-2: Key Future Opportunities

Figure 6-1: BL-B01D1-306 Phase III (NCT06343948) Study – Initiation & Estimated Completion Year
Figure 6-2: BL-B01D1-307 Phase III (NCT06382142) Study – Initiation & Estimated Completion Year
Figure 6-3: BL-B01D1-204-04 Phase II (NCT06471205) Study – Initiation & Estimated Completion Year
Figure 6-4: BL-B01D1-SI-B003-201-04 Phase II (NCT06042894) Study – Initiation & Estimated Completion Year
Figure 6-5: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study – Initiation & Estimated Completion Year
Figure 6-6: BL-B01D1-104 Phase I (NCT05470348) Study – Initiation & Estimated Completion Year
Figure 6-7: KM501-1001 Phase I (NCT05804864) Study – Initiation & Estimated Completion Year
Figure 6-8: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study – Initiation & Estimated Completion Year
Figure 6-9: BL-B01D1-103 Phase I (NCT05262491) Study – Initiation & Estimated Completion Year
Figure 6-10: BL-B01D1-302 Phase III (NCT06382129) Study – Initiation & Estimated Completion Year
Figure 6-11: BL-B01D1-301 Phase III (NCT06382116) Study – Initiation & Estimated Completion Year
Figure 6-12: BL-B01D1-304 Phase III (NCT06500026) Study – Initiation & Estimated Completion Year
Figure 6-13: DM001001 Phase II (NCT06475937) Study – Estimated Initiation & Estimated Completion Year
Figure 6-14: CIBI334A101 Phase I/II (NCT05774873) Study – Estimated Initiation & Estimated Completion Year
Figure 6-15: BL-B01D1-201 Phase II (NCT05785039) Study – Initiation & Estimated Completion Year
Figure 6-16: BL-B01D1-102 Phase I (NCT05393427) Study – Initiation & Estimated Completion Year
Figure 6-17: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study – Initiation & Estimated Completion Year
Figure 6-18: BL-B01D1-202 Phase Ib/II (NCT05803018) Study – Initiation & Estimated Completion Year
Figure 6-19: IMGN151-1001 Phase I (NCT05527184) Study – Initiation & Estimated Completion Year
Figure 6-20: JSKN003-102 Phase I/II (NCT05744427) Study – Initiation & Estimated Completion Year

Figure 7-1: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2025
Figure 7-2: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2025
Figure 7-3: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2025
Figure 7-4: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2025

Figure 9-1: ArbeleBio - Unnamed ADC Platform
Figure 9-2: BiVictriX - Bi-Cygni Therapeutics
Figure 9-3: Duality Biologics – DITAC Platform
Figure 9-4: Duality Biologics – DITAC Platform
Figure 9-5: LigaChem Biosciences – ConjuALL
Figure 9-6: LigaChem Biosciences - Conjugation Method
Figure 9-7: LigaChem Biosciences - ?-Glucuronide Linker
Figure 9-8: LigaChem Biosciences - ?-Glucuronide Linker
Figure 9-9: ProEn Therapeutics - ArtBody? ADC technology
Figure 9-10: Synaffix – Proprietary Technologies
 

List of Tables

Table 1-1: BsADC vs. Conventional ADC
Table 1-2: Bispecific Antibody Formats

Table 4-1: Bispecific Antibody Drug Conjugate Market – Recent Collaborations

Table 6-1: BL-B01D1: Clinical Trials Underway For Lung Cancer